Anti-Amyloid- β Protein agents for the treatment of Alzheimer's Disease: An update on emerging drugs.

Anti-Amyloid-β Protein agents for the treatment of Alzheimer's Disease: An update on emerging drugs. Expert Opin Emerg Drugs. 2020 Aug 10;: Authors: Lozupone M, Solfrizzi V, D'Urso F, Di Gioia I, Sardone R, Dibello V, Stallone R, Liguori A, Ciritella C, Daniele A, Bellomo A, Seripa D, Panza F Abstract INTRODUCTION: Currently available Alzheimer's disease (AD) therapeutics are only symptomatic, targeting cholinergic and glutamatergic neurotransmissions. Several putative disease-modifying drugs in late-stage clinical development target amyloid-β (Aβ) peptide and tau protein, the principal neurophatological hallmarks of the disease. AREAS COVERED: Phase III randomized clinical trials of anti-Aβ drugs for AD treatment were searched in US and EU clinical trial registries and principal biomedical databases until May 2020. EXPERT OPINION: At present, anti-Aβ compounds in Phase III clinical development for AD include four monoclonal antibodies (solanezumab, gantenerumab, aducanumab, BAN2401), the combination of cromolyn sodium and ibuprofen (ALZT-OP1), and two small molecules (levetiracetam, GV-971). These drugs are mainly being tested in subjects during early AD phases or at preclinical stage of familial AD or even in asymptomatic subjects at high risk of developing AD. The actual results support the hypothesis that elevated Aβ represents an early stage in the AD continuum and demonstrate the feasibility of enrolling these h...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Related Links:

I recently collaborated on a review paper covering the history of clinical work on upregulation of nicotinamide adenine dinucleotide (NAD) as an approach to therapy. This is of interest to the aging research community because NAD is important to mitochondrial function. NAD levels diminish with age, alongside a loss of mitochondrial function that is known to contribute to the onset and progression of many age-related conditions. Animal studies and a few clinical trials have indicated that increased NAD levels may improve, for example, cardiovascular function in older individuals, as a result of improved mitochondrial functi...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
The biotech startup is currently completing its first-in-human clinical trial with funding provided in part by a grant from the Alzheimer's Association.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
In this study, we applied senescence-accelerated mouse-prone 8 mice as the AD animal model, used the Morris water maze, and applied hematoxylin and eosin staining, immunofluorescence double staining, and Western blotting, to explore the effects and potential mechanisms of action of electroacupuncture. In summary, this study suggested that electroacupuncture treatment could improve the learning and memory abilities (p
Source: Neural Plasticity - Category: Neurology Authors: Tags: Neural Plast Source Type: research
ntilde;a-Ortega F Abstract For more than five decades, the field of Alzheimer's disease (AD) has focused on two main hypotheses positing amyloid-beta (Aβ) and Tau phosphorylation (pTau) as key pathogenic mediators. In line with these canonical hypotheses, several groups around the world have shown that the synaptotoxicity in AD depends mainly on the increase in pTau levels. Confronting this leading hypothesis, a few years ago, we reported that the increase in phosphorylation levels of dendritic Tau, at its microtubule domain (MD), acts as a neuroprotective mechanism that prevents N-methyl-D-aspartate receptor...
Source: Neural Plasticity - Category: Neurology Authors: Tags: Neural Plast Source Type: research
This paper discusses dysfunction of glycosyltransferases as a factor and potential therapeutic target in neurodegenerative diseases including ALS, Alzheimer, Huntington, and Parkinson disease.Brain
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
A new film "The Artist’s Wife" tells the story of a family navigating an Alzheimer's diagnosis. The film will be available on September 25, 2020 on all On Demand platforms, including Amazon, Apple TV, iTunes, YouTube, Google Play, Vudu, and others...
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care syndicated Source Type: blogs
To coincide with World Alzheimer ’s Day, pain assessment app PainChek has published a new report on pain and dementia. 
Source: mobihealthnews - Category: Information Technology Source Type: news
Source: Neuropsychiatric Disease and Treatment - Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Alzheimer's disease neuropathologies (amyloid- β and tau) frequently co-exist to varying degrees in Lewy body dementias (LBD), which include dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD).
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Tags: Review article Source Type: research
Robert (Bob) May, Baron May of Oxford, a long-time International Member of the National Academy of Sciences, passed away on April 28, 2020, in Oxford, United Kingdom, from “frailties of old age, Alzheimer's disease, and pneumonia,” at the age of 84. He is survived by his wife Judith, his daughter...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Retrospectives Source Type: research
More News: Alzheimer's | Brain | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Ibuprofen | Neurology | Sodium